3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Carcinoma, Hepatocellular
30
Neoplasms
19
Carcinoma, Renal Cell
16
Melanoma
10
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
9
Endometrial Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Liver Neoplasms
4
Carcinoma, Transitional Cell
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Lymphoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Carcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Solid Tumors
2
Osteosarcoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Glioma
2
Diabetes Mellitus, Insulin-Dependent, 12
2
Interventions
Gemcitabine
12
Cisplatin
10
pembrolizumab
7
Fluorouracil
7
Leucovorin
6
Oxaliplatin
5
durvalumab
3
Capecitabine
3
zanidatamab
2
Paclitaxel
2
Irinotecan
2
Folfox protocol
2
Bevacizumab
2
vandetanib
1
tucatinib
1
trastuzumab deruxtecan
1
seribantumab
1
merestinib
1
lenvatinib
1
irinotecan sucrosofate
1
galactomannan
1
fludarabine
1
exatecan
1
bintrafusp alfa protein, human
1
becatecarin
1
aldesleukin
1
Trastuzumab
1
Temozolomide
1
Tegafur
1
S 1 (combination)
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gallbladder Neoplasms
×
lenvatinib
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled